Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

NCT01120249 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT01120249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01120249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 3
Overall status
Completed
Start date
April 1, 2011
Completion date
September 1, 2025
Enrollment
1,545 (actual)
Sites
1,003

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer